Benzinga

Benzinga

Benzinga

vendredi, août 28

IDEAYA Biosciences Inc

IDYANASDAQ
Trade with Public
Trade with Public
$40.51
-1.26-3.02%
Dern. MÀJ: Aug 28, 1:39 PM
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

IDEAYA Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for IDEAYA Biosciences (IDYA).

Price Target Range — 13 Quarters

Analyst Consensus — 19 Analysts

1S.Buy
16Buy
2Hold
Consensus RatingBuy# Analysts19Avg. Consensus PT$52Upside to Avg. PT+28.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026Truist SecuritiesGregory RenzaPT CutBuy$63→$59
Aug 5, 2026WedbushRobert DriscollPT RaiseOutperform$58→$60
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $65 to $63.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved